CSWT workshop and press conference in Prague
A workshop and press conference on cardiac shock wave therapy (CSWT) took place on 15 March 2024 at the Fyzioklinika in Prague. The Fyzioklinika is the first clinic in the Czech Republic to use the MODULITH® SLC for non-invasive treatment of ischaemic heart disease.
Cardiologists and medical professionals from Germany and the Czech Republic discussed current topics in CSWT relating to the treatment of patients with ischaemic heart disease as well as sharing their knowledge on the use of the MODULITH® SLC. The journalists at the press conference and subsequent workshop showed a high level of interest in this form of therapy.
In the workshop, Dr Dilana Hazer-Rau from STORZ MEDICAL elaborated on the non-invasive CSWT method and introduced the MODULITH® SLC. She presented the benefits and the current state of research in this field. Dr Ernst Marlinghaus from STORZ MEDICAL discussed the effects of CSWT based on the results of experimental and clinical studies for a range of applications. Next up to speak was Dr Achim Gutersohn, a cardiologist who has been using the device for many years as Chief Physician of the Department of Internal Medicine and Cardiology at St. Marienhospital Vechta and Director of the Cardiology departments in Cloppenburg and Vechta, Germany. He reported on his clinical experience using CSWT to treat patients with ischaemic heart disease. In the afternoon, he gave a practical demonstration on the use of the MODULITH® SLC in the treatment of angina pectoris and heart failure.
Prof. Martin Busse from the Institute of Sports Medicine and Prevention at Leipzig University Hospital and Dr Christian Meyer, Specialist in Internal Medicine and Cardiology with a focus on Special Cardiovascular Prevention at Schlosspraxen Meyer in Hachenburg, Germany, shared valuable experiences and provided interesting insights from their everyday clinical work in cardiology. The discussions underlined the significance of the scientific and clinical use of this non-invasive method for treating patients with ischaemic heart disease.
There are currently more than 60 CSWT devices in use worldwide. Extending the range of indications from angina pectoris to ischaemic heart failure opens up new opportunities in patient selection and therapeutic use in addition to the associated improvement in cost-effectiveness for users.
